TK-39

About Tosk

Tosk is a clinical-stage biotechnology company developing a novel class of small molecule adjunctive therapies designed to mitigate the severe, dose-limiting side effects of standard cancer treatments. Its lead candidate, TK-90, has completed proof-of-concept studies for preventing chemotherapy-induced mucositis, while other pipeline programs target cardiotoxicity, nephrotoxicity, and oncogenic KRAS. Leveraging a unique discovery platform and led by an experienced management team, Tosk seeks to address a significant unmet need in supportive oncology care with cost-effective, orally available drugs.

Therapeutic Areas